An antioxidant, saccharification inhibitor and its application

Abstract

The invention discloses an antioxidant and glycation inhibitor, and the preparation method thereof comprises the following steps: pretreatment; extraction; and concentration. The antioxidant and glycation inhibitor of the invention is a kava kava extract, which has an antioxidant effect, inhibits the glycation of proteins, can inhibit the activity of collagenase, inhibits the synthesis and secretion of cytokines (IL-12) (inhibits cell aging), and improves the effect of skin sagging. It can also be used in a variety of cosmetics and has good compatibility with a variety of cosmetic ingredients.

Description

Technical Field

[0001] The invention relates to an antioxidant, a saccharification inhibitor and an application thereof, relates to A61K, and specifically relates to the field of cosmetic preparations. Background Art

[0002] Anti-skin aging has been the pursuit of beauty lovers since ancient times. With the advancement of science and technology, research on skin aging has progressed to the cellular level. The known causes of skin cell aging include oxidative damage to cells or saccharification of proteins that induce the production of inflammatory cytokines in surrounding cells. Therefore, in order to inhibit skin aging, skin topical agents need to inhibit oxidative damage to cells, inhibit protein saccharification, and inhibit the secretion of aging-inducing factors. Kava Kava is a plant of the genus Piperaceae. It is used in cosmetics in traditional processes to inhibit fat synthesis and moisturizing effects, but the antioxidant effect, anti-protein saccharification effect, and the effect of inhibiting the synthesis of aging-inducing factors are not disclosed. And the extract in this application also has the effect of inhibiting collagenase activity and improving skin sagging. Summary of the invention

[0003] In order to improve the extraction rate of the effective ingredients of kava kava, so that it has the effects of anti-oxidation, inhibiting glycation, inhibiting collagenase activity, inhibiting the secretion of aging-inducing factors, and improving relaxation, the first aspect of the present invention provides an antioxidant and glycation inhibitor, and the preparation method thereof comprises the following steps:

[0004] (1) Wash the plants to be extracted, remove foreign matter from the surface, dry them, and crush them;

[0005] (2) mixing and contacting the crushed plant to be extracted with an extractant, extracting, and filtering to obtain a crude plant extract;

[0006] (3) The crude plant extract is concentrated under reduced pressure to obtain a plant concentrate, and water and a preservative are added to the plant concentrate to obtain a plant extract.

[0007] As a preferred embodiment, the plant to be extracted is a plant of the Piperaceae family, the plant of the Piperaceae family is Kava Kava (Macropiper excelsum), and the extraction part of the Kava Kava is the leaves.

[0008] As a preferred embodiment, the mass ratio of the kava kava leaves to the extractant is 1:(4-6), and further preferably, the mass ratio of the kava kava leaves to the extractant is 1:5.

[0009] As a preferred embodiment, the extractant is selected from one or a combination of water, lower alcohols, polyols, ester extractants, ketone extractants, ether extractants, and hydrocarbon extractants.

[0010] As a preferred embodiment, the lower alcohol is selected from one or a combination of methanol, ethanol, and propanol, and the polyol is selected from one or a combination of ethylene glycol, propylene glycol, butylene glycol, and glycerol.

[0011] As a preferred embodiment, the ester extractant is selected from one or a combination of ethyl acetate, butyl acetate, and methyl propionate; the ketone extractant is selected from one or a combination of acetone and methyl ethyl ketone; the ether extractant is selected from one or a combination of ethyl ether and isopropyl ether; and the hydrocarbon extractant is n-hexane.

[0012] As a preferred embodiment, the extractant is a mixed solution of ethanol and water or a mixed solution of butanediol and water, and the butanediol is selected from one or a combination of 1,2-butanediol, 1,3-butanediol, and 1,4-butanediol.

[0013] As a preferred embodiment, the mass fraction of ethanol in the mixed solution of ethanol and water is 10-60%, and the mass fraction of butanediol in the mixed solution of butanediol and water is 10-70%. Further preferably, the butanediol is 1,3-butanediol.

[0014] As a preferred embodiment, the mass fraction of ethanol in the mixed solution of ethanol and water is 45-55%. Further preferably, the mass fraction of ethanol in the mixed solution of ethanol and water is 50%.

[0015] As a preferred embodiment, the extraction parameters in step 2 are: extraction temperature is 0-80°C, extraction time is 1-168h; pH of the crude plant extract is 3-9.

[0016] As a preferred embodiment, the extraction parameters in step 2 are: extraction temperature is 30-50° C., extraction time is 1.5-3 h; and pH of the crude plant extract is 4-8.

[0017] As a preferred embodiment, the preservative in step 3 is 1,3-butanediol, and the total added mass fraction of 1,3-butanediol is 35-55%.

[0018] As a preferred embodiment, the pH is adjusted by adding an acid-base regulator, wherein the acid-base regulator is selected from one or a combination of sodium hydroxide, sodium carbonate, potassium hydroxide, sodium citrate, hydrochloric acid, phosphoric acid, and sulfuric acid.

[0019] The second aspect of the present invention provides an application of an antioxidant and a glycation inhibitor, which is applied to daily chemical products, wherein the daily chemical products are selected from one of lotions, creams, lotions, essences, peel-off masks, lipsticks, foundations, sheet masks, liquid foundations, cosmetic pressed powders, blushers, whitening powders, facial cleansers, body shampoos, hair shampoos, soaps, hair growth agents, and bath agents.

[0020] As a preferred embodiment, the daily chemical products include one or a combination of hydrocarbon additives, ester additives, triglyceride additives, fatty acids, higher alcohols, surfactants, polyols, thickening gels, antioxidants, UV protection agents, colorants, preservatives, pH regulators, moisturizers, skin conditioners, plant ingredients, and microbial ingredients.

[0021] As a preferred embodiment, the hydrocarbon additive is selected from one or a combination of squalane, vaseline, and microcrystalline wax; the ester additive is selected from one or a combination of jojoba oil, carnauba wax, and octyldodecyl oleate; the triglyceride additive is selected from one or a combination of olive oil, tallow, and coconut oil; the fatty acid is selected from one or a combination of stearic acid, oleic acid, and retinoic acid; the higher alcohol is selected from one or a combination of oleyl alcohol, stearyl alcohol, and octyldodecyl alcohol; the surfactant is selected from sulfosuccinate, polyoxyethylene alkyl sodium sulfate anionic surfactant, alkyl betaine salt amphoteric surfactant, The invention relates to a surfactant, a dialkylammonium salt cationic surfactant, a sorbitan fatty acid ester polyoxyethylene adduct, a fatty acid monoglyceride polyoxyethylene adduct, a polyoxyethylene alkyl ether, and a polyoxyethylene fatty acid ester nonionic surfactant, or a combination thereof; the polyol is selected from one or a combination of polyethylene glycol, glycerol, and 1,3-butylene glycol; the skin conditioner is selected from one or a combination of dipotassium glycyrrhizinate, hyaluronic acid, hyaluronate, and hydroxypinacolone retinoic acid ester; the plant component is selected from but not limited to camellia extract; the microbial component is selected from but not limited to bifidobacterium culture fluid components.

[0022] As a preferred embodiment, it is applied to daily chemical products, and the raw materials for preparing the daily chemical products include, by weight percentage: 0.5-2% of the extract of Example 1, 1-5% of 1,3-butanediol, 0.2-0.3% of paraben, and purified water supplemented to 100%.

[0023] As a preferred embodiment, it is applied to daily chemical products, and the raw materials for preparing the daily chemical products include, by weight percentage: 0.5-2% of the extract of Example 1, 0.5-3% of β-glucan, 0.2-6% of β-glucan, 1-5% of 1,3-butanediol, 0.05-0.1% of sodium citrate, and purified water supplemented to 100%.

[0024] As a preferred embodiment, the invention is applied to daily chemical products, wherein the raw materials for preparing the daily chemical products include, by weight percentage: 0.5-2% of the extract of Example 1, 0.05-1% of hydroxypinacolone retinoic acid ester, 1-3% of bifidobacterium culture solution, 0.1-5% of 1,3-butanediol, 0.5-0.8% of phenoxyethanol, 0.05-0.1% of sodium citrate, and purified water supplemented to 100%.

[0025] As a preferred embodiment, the invention is applied to daily chemical products, wherein the raw materials for preparing the daily chemical products include, by weight percentage: 0.5-2% of the extract of Example 1, 0.2-2% of hydroxypinacolone retinoic acid ester of Centella asiatica extract, 0.8-2% of sodium hyaluronate, 0.1-5% of 1,3-butylene glycol, 0.5-0.8% of phenoxyethanol, 0.05-0.1% of sodium citrate, and purified water supplemented to 100%.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] (1) The antioxidant and glycation inhibitor of the present invention is a kava kava extract, and a 50% by mass ethanol aqueous solution is used as an extractant, which can increase the dissolution rate of the active ingredients and reduce the complexity of subsequent separation steps.

[0028] (2) The antioxidant and glycation inhibitor of the present invention is a kava kava extract. Adding 30% by mass of 1,3-butanediol to the kava kava concentrate can improve the stability of the kava kava extract and increase the solubility of the active ingredients.

[0029] (3) The antioxidant and glycation inhibitor of the present invention is a kava kava extract, and the extraction temperature is 40° C. and the extraction time is 2 h, which can improve the extraction yield of the extract and maintain the structural stability of the effective ingredients.

[0030] (4) The antioxidant and glycation inhibitor of the present invention is kava kava extract, and the solid-liquid ratio of crushed kava kava leaves to the extractant is 1:(4-6), which can increase the extraction rate of the active ingredients in the kava kava extract while reducing the extraction cost.

[0031] (5) The antioxidant and glycation inhibitor of the present invention is kava kava extract, which has an antioxidant effect, inhibits protein glycation, can inhibit the activity of collagenase, inhibits the synthesis and secretion of cytokines (IL-12) (inhibits cell aging), and improves skin sagging.

[0032] (6) The antioxidant and glycation inhibitor of the present invention is kava kava extract, which can be used in a variety of cosmetics and has good compatibility with a variety of cosmetic ingredients. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 This is a graph showing changes in skin elasticity for four weeks without applying lotion.

[0034] Figure 2 This is a graph showing changes in skin elasticity after using the lotion of Comparative Example 1 for four weeks;

[0035] Figure 3 This is a graph showing changes in skin elasticity after using the lotion of Application Example 1 of the present application for four weeks. DETAILED DESCRIPTION

[0036] Example 1

[0037] A method for preparing an antioxidant and saccharification inhibitor comprises the following steps:

[0038] (1) Wash the plants to be extracted, remove foreign matter from the surface, dry them, and crush them;

[0039] (2) mixing and contacting the crushed plant to be extracted with an extractant, extracting, and filtering to obtain a crude plant extract;

[0040] (3) The crude plant extract is concentrated under reduced pressure to obtain a plant concentrate, and water and a preservative are added to the plant concentrate to obtain a plant extract.

[0041] The plant to be extracted is the leaves of kava kava; the mass ratio of the kava kava leaves to the extractant is 1:5. 100g of kava kava leaves and 500g of the extractant.

[0042] The extractant is a mixed solution of ethanol and water, and the mass fraction of ethanol in the mixed solution of ethanol and water is 50%.

[0043] The extraction temperature is 40° C., the extraction time is 2 hours, the extraction acid-base pH is 6.5, and the acid-base regulator is sodium citrate, with an overall added mass fraction of 0.05%.

[0044] In the step 3, the preservative is 1,3-butanediol, and the total added mass fraction of 1,3-butanediol is 30%.

[0045] The final plant extract was a yellow solution with a mass of 4.0 kg and a solid content of 0.28%.

[0046] Example 2

[0047] A method for preparing an antioxidant and saccharification inhibitor, the specific steps are the same as those of Example 1, except that the extractant is a mixed solution of ethanol and water, and the mass fraction of ethanol in the mixed solution of ethanol and water is 20%.

[0048] The final plant extract was a yellow solution with a mass of 4.2 kg and a solid content of 0.22%.

[0049] Performance Testing

[0050] 1. Evaluation test of antioxidant effect (DPPH free radical elimination effect)

[0051] 2.4 parts of DPPH were dissolved in 20 parts of ethanol, and 20 parts of purified water were added thereto to prepare a DPPH solution. To 22.4 parts of the DPPH solution, 19.2 parts of an 18 v / v% ethanol solution and 4.8 parts of a 2M acetic acid-sodium acetate buffer solution (pH 5.5) were added to prepare a DPPH addition solution. In addition, in order to eliminate the influence of the color tone of the extract itself on the test, a 50 v / v% ethanol solution was used instead of the DPPH solution, and a solution mixed with an 18 v / v% ethanol solution and a 2M acetic acid-sodium acetate buffer solution was used as a control solution. The kava kava extract of the present invention (the extract solution of Example 1) was then diluted with purified water to prepare a sample solution, and the final mass concentrations were 0.5%, 1.0%, and 2.0%, respectively. The sample solution and the DPPH-added solution were mixed in a ratio of 1:3, and after standing at room temperature for 10 minutes, the difference between the absorbance at 550nm when each test solution was mixed with the DPPH-added solution and the absorbance at 550nm when each test solution was mixed with the control solution was measured to confirm the residual amount of DPPH free radicals. In addition, as a control group, a 30% volume fraction 1,3-butanediol aqueous solution [control group (1.3-BG)] (2.0wt%) was used instead of the extract solution of Example 1, and the same operation as above was performed to determine the relative value of the DPPH free radical residual rate when each sample was added relative to the DPPH free radical residual rate obtained here. The test results are shown in Table 1.

[0052] Table 1

[0053]

[0054] As shown in Table 1, it was confirmed that the extract of the present invention has an excellent active oxygen (DPPH radical) elimination effect. This shows that the kava kava extract of the present invention inhibits oxidative damage to cells and inhibits cell aging.

[0055] 2. Evaluation test of protein glycation inhibition effect

[0056] The AGE generation inhibitory effect, i.e., the protein glycation inhibitory effect, was evaluated by the fluorescence generation and color development of BSA (bovine serum albumin) mediated by glyceraldehyde. First, 50 μL of the kava kava extract of the present invention (the extract solution of Example 1), 50 μL of a 50 mg / mL BSA aqueous solution, 50 μL of an 8 mM glyceraldehyde aqueous solution, and 50 μL of a PBS solution were mixed and stirred to prepare a sample solution. The concentration of the sample solution was adjusted so that the final mass concentration of the extract solution of Example 1 was 0.25%, 0.5%, and 1.0%, respectively. The sample solution was allowed to stand at 37° C. for 24 hours, and then the fluorescence generation (excitation: 355 nm, emission: 460 nm: fluorescence microplate reader (Fluoroscan Acent, manufactured by Thermo Fisher Scientific)) and absorbance (wavelength 405 nm: microplate reader (Multiskan FC, manufactured by Thermo Scientific)) were measured for each sample solution. In addition, as a control, 30% by volume 1,3-butanediol [control group (1.3-BG)] (1.0%) was used instead of the extract of Example 1, and the same operation was performed to obtain the fluorescence measurement value obtained here, as well as the relative value of the absorbance of each sample solution and the relative value and percentage (%) of the fluorescence measurement value as the protein glycation rate (%). The same test was also performed when the extract of Example 1 was replaced by adding 1mM aminoguanidine (AG) as a positive control. The calculation results of the absorbance are shown in Table 2, and the calculation results of the fluorescence value are shown in Table 3.

[0057] Table 2

[0058]

[0059]

[0060] Table 3

[0061]

[0062] As shown in Tables 2 and 3, the kava kava extract of the present invention has a protein glycation inhibitory effect, which shows that the kava kava extract of the present invention inhibits cell glycation and inhibits cell aging.

[0063] 3. Evaluation test of the activity inhibition effect of SA-βGal

[0064] SA-βGal (senescence associated beta galactosidase) is activated in aged cells and is therefore used as an indicator for evaluating aging on a cell-by-cell basis. Cellular aging is evaluated using the SA-βGal indicator.

[0065] Step (1) Inducing saccharification of BSA

[0066] A 50 mg / mL BSA aqueous solution was mixed with an 8 mM glyceraldehyde aqueous solution and cultured at 37°C for 7 days to induce the saccharification of BSA. A sample addition zone was set up, and the Kava Kava extract of the present invention (the extract solution of Example 1) was added as a sample solution to the culture solution that induced the saccharification of BSA. The concentration of the sample solution was adjusted so that the final mass concentrations of the extract solution of Preparation Example 1 were 0.125%, 0.25%, and 0.5%, respectively. On the other hand, a control group was set up to add 30% by volume 1,3-butanediol [1.3-BG] (0.5wt%) instead of the extract solution of Example 1, and the same operation was performed.

[0067] Step (2) SA-βGal activity measurement

[0068] NHDF (fibroblasts from a 36-year-old donor) were cultured at 9.0×10 4 / well of a 24-well plate, and cultured in Eagle's minimum essential medium containing 0.5% newborn calf serum for 24 hours. Then, Eagle's minimum essential medium containing 0.5% newborn calf serum was replaced with serum-free medium, and the culture solution of the test area containing the glycated BSA prepared in the above step (1) or the culture solution of the control area was added, and culture was continued for another 6 days. For the comparison area (1), a culture solution containing the same concentration of fresh BSA (i.e., BSA without induced glycation) was added to the well plate cultured with NHDF instead of the culture solution containing the glycated BSA, and cultured for 6 days in the same manner. After the culture, the medium was removed, SPiDER-βGal (SG02: Tongren Chemical) was added, and incubated at 37°C for 30 minutes. Then, the cells were detached with trypsin, and the fluorescence amount of each cell (Ex=488 / Em=538nm) was measured by flow cytometry. The fluorescence values ​​of the sample-added area and the comparison area were calculated when the fluorescence value of the control area was 100, and the result was taken as the activity rate of SA-βGal.

[0069] Table 4

[0070]

[0071] As shown in Table 4, the kava kava extract of the present invention inhibits the activity of SA-βGal. The kava kava extract of the present invention inhibits cell aging.

[0072] 4. Inhibition of the synthesis of SASP factor (IL-12)

[0073] Step (1) Inducing saccharification of BSA

[0074] A 50 mg / mL BSA aqueous solution was mixed with an 8 mM glyceraldehyde aqueous solution and cultured at 37°C for 7 days to induce the saccharification of BSA. A sample addition zone was set, and the Kava Kava extract of the present invention (the extract solution of Example 1) was added to the culture solution for inducing the saccharification of BSA as a sample solution. A comparison zone (1) was set to add 30% by volume 1,3-butanediol [1.3-BG] (0.5 wt%) instead of the extract solution of Example 1, and the same operation was performed.

[0075] Step (2) Measurement of the amount of SASP factor (IL-12) synthesized

[0076] NHDF (fibroblasts from a 36-year-old donor) were cultured at 9.0×10 4 / well in a 24-well plate, and cultured for 24 hours in Eagle's minimum essential medium containing 0.5% newborn calf serum. Then, Eagle's minimum essential medium containing 5% newborn calf serum was replaced with serum-free medium, and the culture solution containing the glycated BSA prepared in the above step (1) was added to the test area, and the culture was continued for 6 days. Control group: NHDF was replaced with a well plate containing fibroblasts (NB1RGB) from newborns, and the test area was set up without adding the above glycated BSA for culture; comparison area (2): NHDF was set up in the well plate without adding the above glycated BSA for culture, and the test area was cultured for 6 days in the same way. After culture, the culture supernatant was recovered and analyzed using Human Cytokine Antibody Array (human cytokine antibody chip) (42Target 8memb) ab133997 (Abcam). The activity of SA-βGal was expressed as a relative value when the culture supernatants of the sample-added area and the comparison areas (1) and (2) were analyzed, with the value when the culture supernatant of neonatal fibroblasts was analyzed being 100. The results are shown in Table 5.

[0077] Table 5

[0078] Sample IL-12 synthesis rate (%) Control area 100.0 Example 1 106.5 Comparison Area (1) 130.6 Comparison Area (2) 122.6

[0079] As shown in Table 5, the kava kava extract of the present invention has an effect of inhibiting cytokine (IL-12) which is one of the SASP factors. This indicates that the kava kava extract of the present invention has an effect of inhibiting cell aging induction.

[0080] 5. Evaluation test of collagenase activity inhibition

[0081] Step (1) Inducing saccharification of BSA

[0082] A 50 mg / mL BSA aqueous solution was mixed with an 8 mM glyceraldehyde aqueous solution and cultured at 37°C for 7 days to induce the saccharification of BSA. A sample addition zone was set, and the Kava Kava extract of the present invention (the extract solution of Example 1) was added to the culture solution for inducing the saccharification of BSA as a sample solution. A comparison zone (1) was set to add 30% by volume 1,3-butanediol [1.3-BG] (0.5 wt%) instead of the extract solution of Example 1, and the same operation was performed.

[0083] Step (2) Determination of collagenase activity

[0084] NHDF (fibroblasts from a 36-year-old donor) were cultured at 9.0×10 4 / well in a 24-well plate and cultured in Eagle's minimum essential medium containing 0.5% newborn calf serum for 24 hours. Then, Eagle's minimum essential medium containing 5% newborn calf serum was replaced with serum-free medium, and the culture medium containing the glycated BSA prepared in step (1) was added to the sample addition area, and the culture was continued for another 6 days. Control area: 9.0×10 4 / well, the test area that was cultured without adding the above-mentioned saccharified BSA was cultured in the same way for 6 days. After culture, the culture supernatant was recovered and used as a collagenase solution. The collagenase activity was determined using the collagenase assay kit of Primarycell. 50μL of the above-mentioned collagenase solution and 50μL of FITC-labeled type I collagen matrix solution were added to the microtube. After reacting at 37°C for 30 minutes, 300μL of the reaction termination solution was added, the unreacted collagen matrix was precipitated by centrifugation, and the fluorescence intensity of the supernatant was measured (Ex=355, Em=460). The measurement results are expressed as relative values ​​with the value of the culture supernatant of NHDF cultured without adding saccharified BSA as 100. The results are shown in Table 6.

[0085] Table 6

[0086] Sample Collagenase activity rate (%) Control area 100.0 Example 1 83.8 Comparison Area (1) 165.5

[0087] As shown in Table 6, the kava kava extract of the present invention has an effect of inhibiting collagenase activity. This shows that the kava kava extract of the present invention has an effect of inhibiting the decomposition of dermal collagen and improving skin elasticity.

[0088] Application Example 1

[0089] An application of an antioxidant and saccharification inhibitor is applied to daily chemical products. The raw materials for preparing the daily chemical products include, by weight percentage: 1% of the extract of Example 1, 5% of 1,3-butylene glycol, 0.2% of paraben, and purified water supplemented to 100%.

[0090] Application Example 2

[0091] An application of an antioxidant and a saccharification inhibitor is applied to daily chemical products. The raw materials for preparing the daily chemical products include, by weight percentage: 0.5% of the extract of Example 1, 0.5% of beta-glucan, 0.2% of beta-glucan, 1% of 1,3-butanediol, 0.05% of sodium citrate, and purified water supplemented to 100%.

[0092] Application Example 3

[0093] An application of an antioxidant and a saccharification inhibitor is applied to daily chemical products. The raw materials for preparing the daily chemical products include, by weight percentage: 2% of the extract of Example 1, 0.05% of hydroxypinacolone retinoic acid ester, 1% of bifidobacterium culture solution, 0.1% of 1,3-butanediol, 0.5% of phenoxyethanol, 0.05% of sodium citrate, and purified water supplemented to 100%.

[0094] Application Example 4

[0095] An application of an antioxidant and a saccharification inhibitor is applied to daily chemical products. The raw materials for preparing the daily chemical products include, by weight percentage: 2% of the extract of Example 1, 0.2% of hydroxypinacolone retinoic acid ester of Centella asiatica extract, 0.8% of sodium hyaluronate, 0.1% of 1,3-butylene glycol, 0.5% of phenoxyethanol, 0.05% of sodium citrate, and purified water supplemented to 100%.

[0096] Application Comparative Example 1

[0097] An application of an antioxidant and a saccharification inhibitor is applied to daily chemical products. The specific raw materials of the daily chemical products are the same as those of application example 1, except that the extract of example 1 is replaced by a 1,3-butanediol aqueous solution with a mass fraction of 30%.

[0098] Performance Testing

[0099] Skin elasticity assessment test

[0100] Three test sites were set on the inner forearms of five subjects (women aged 20 to 30 years old), as the unapplied area, the comparative control lotion application area of ​​the application comparison example 1, and the lotion application area containing the application example 1 of the present invention. First, the elasticity (R2) of the skin before applying the lotion was measured using CUTOMETER (Courage + Khazaka, Germany) as the initial value. Each lotion was then applied to the test site twice a day for 4 weeks. After the test, the skin elasticity (R2) was measured using CUTOMETER in the same way as at the beginning of the test, and the average of the measured values ​​of the five people was calculated, and the average change rate (%) was calculated.

[0101] The test results are as follows Figures 1 to 3shown.

[0102] In such Figure 1 , 2 As shown, in the area without applying the sample, the elasticity of the skin decreased by 4.5%, while the area applying the lotion of comparative example 1 decreased by 2.8%. On the other hand, in the area applied with the lotion of application example 1 of the present invention, the elasticity of the skin improved by 0.6%. This shows that the extract of the present invention has the effect of improving skin sagging.

Claims

1. An antioxidant and glycation inhibitor, characterized in that: The preparation method comprises the following steps: (1) Wash the plants to be extracted, remove foreign matter from the surface, dry them, and crush them; (2) mixing the crushed plant to be extracted with an extractant, extracting, and filtering to obtain a crude plant extract; (3) concentrating the crude plant extract under reduced pressure to obtain a plant concentrate, and adding water and a preservative to the plant concentrate to obtain a plant extract; The plant to be extracted is a plant of the Piperaceae family, the plant of the Piperaceae family is Kava Kava (Macropiper excelsum), and the extraction part of the Kava Kava is the leaves; The extractant is a mixed solution of ethanol and water or a mixed solution of butanediol and water, wherein the mass fraction of ethanol in the mixed solution of ethanol and water is 10-60%; the mass fraction of butanediol in the mixed solution of butanediol and water is 10-70%; The extraction parameters in step (2) are: extraction temperature is 30-50° C., extraction time is 1.5-3 h; and pH of the crude plant extract is 3-9.

2. The antioxidant and glycation inhibitor according to claim 1, characterized in that: The butanediol is selected from 1,2-butanediol, 1,3-butanediol, 1,4-butanediol or a combination of the two.

3. An application of the antioxidant and glycation inhibitor according to any one of claims 1 to 2, characterized in that: Used in daily chemical products.

4. The use of the antioxidant and glycation inhibitor according to claim 3, characterized in that: The daily chemical product is selected from one of lotion, cream, lotion, essence, peel-off mask, lipstick, smear mask, liquid foundation, pressed powder, blush, loose powder, facial cleanser, body shampoo, hair shampoo, soap, hair growth agent and bath agent.

5. The use of the antioxidant and glycation inhibitor according to claim 3, characterized in that: The daily chemical product is selected from foundation.

6. The use of the antioxidant and glycation inhibitor according to claim 3, characterized in that: The daily chemical products include one or a combination of hydrocarbon additives, triglyceride additives, fatty acids, higher alcohols, surfactants, polyols, thickening gels, antioxidants, ultraviolet protection agents, colorants, preservatives, pH regulators, moisturizers, skin conditioners, plant ingredients, and microbial ingredients.

7. The use of the antioxidant and glycation inhibitor according to claim 3, characterized in that: The daily chemical product comprises an ester auxiliary agent.

Images